J&J is jettisoning two of its promised blockbuster drugs, and it couldn't come at a worse time
Just 5 months after trying to convince investors that they were on to a large pipeline of blockbusters heading to the market, J&J has already decided that two of them are essentially worthless, or just too dangerous to use.
The writing was already on the wall months ago for sirukumab, once a top prospect for rheumatoid arthritis until its partners at GlaxoSmithKline suddenly walked out. Earlier this year, though, a panel of outside experts voted down the marketing application, fretting over an unexplained imbalance in deaths in the study. The inevitable formal rejection followed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
